EGFR and non-small cell lung carcinoma: Several large clinical studies have proved that epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in NSCLC patients carrying sensitive EGFR mutations 1, 2, 3, 4.